Our Research
Our Research
Pipeline
Pipeline
We are a research-driven biotech company dedicated to the discovery of first-in-class therapies addressing unmet needs. Our platforms and portfolio deliver NCEs and protein therapeutics against novel targets of relevance in oncology and neurodegeneration.
Ubi-Plex® DUB Platform
Almac Discovery’s Ubi-Plex® platform enables the discovery of selective deubiquitinase inhibitors, integrating target identification, assays and medicinal chemistry to deliver first-in-class therapies across oncology and neurodegenerative diseases and other high-need indications.
Protein Drug Conjugates
With the increasing number of antibody-drug conjugate approvals, including for use in the adjuvant setting (Kadcyla®), and with a growing number of ADCs entering clinical trials, the targeted delivery of cytotoxic agents to cancer cells is proving to be a powerful approach for the treatment of both haematological malignancies and solid tumours.
Wee 1
Almac Discovery has discovered several novel sub-series of small molecule Wee1 inhibitors through focused medicinal chemistry efforts (including structure based design). We have optimized our lead compounds into highly potent and selective inhibitors of Wee1 that demonstrate potent anti-proliferative activity in a variety of cancer cell lines both in combination and as single agents.
USP7
Ubiquitin specific protease 7 (USP7) is a member of the deubiquitinating enzyme class that contains 106 representatives in human cells. USP7 removes the post-translational tag ubiquitin from several protein targets 1. USP7 best characterised role is the removal of ubiquitin from the oncogene MDM2 and thus regulating the tumour suppressor protein p53 2.